This site is intended for health professionals only

Thursday 22 August 2019
Share |

Latest News

Dupilumab reaches primary and secondary endpoints in paediatric trial

Thursday 8th August 2019
A pivotal Phase III trial evaluating Dupixent® (dupilumab) in severe atopic dermatitis in children has met its primary and secondary endpoints. 
The topline data show that for children with severe atopic dermatitis (covering nearly 60% of their skin surface on average), adding Dupixent to standard-of-care topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching and health-...
Fri, 26 Jul 2019
New research from the LEO Foundation Skin Immunology Research Center at the University of Copenhagen shows, surprisingly, that antibiotics inhibit cancer in the skin in patients with rare type of lymphoma
Thu, 25 Jul 2019
A simple finger-prick blood test could help prevent unnecessary prescribing of antibiotics for people with COPD
Thu, 25 Jul 2019
Australian researchers have successfully completed a human trial on a vaccine designed to eliminate the risk of a severe allergic reaction to European honeybee stings
Thu, 18 Jul 2019
Research has shown that projection neurons are damaged by the body's own immune cells, and that this damage could underpin the brain shrinkage and cognitive changes associated with multiple sclerosis
Thu, 18 Jul 2019
Ribociclib in combination with fulvestrant will be available on the NHS with immediate effect, providing approximately 5300 a year in England and Wales with a new option for their advanced breast cancer
Thu, 11 Jul 2019
Authorisation based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug regimen through 48 weeks, with no cases of resistance